d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
i>credit historyMortgage lenders use all of these fa
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
tors and more to determine what kind of a risk you are. The ri
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
skier you are the more likely they are to increase your intere
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
t rate. This increase is compensation to the lender is compens
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ation for lending to a higher risk borrower.
Interest Rate Of
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ered Too High?
Mortgage add up all your risks and offer you a
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
interest rate accordingly.
The higher your interest rate is
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
the higher your monthly payment is.
For some borrowers the in
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
erest rate may be too high.
You may be able to "buy down" you
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
r interest rate by paying the lender money up front.
In a pur
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
hase loan you may be able to use a closing cost credit towards
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
this. In a refinance you may be able to use some of your equi
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
y to pay for the buy down. In either of these two ways you can
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
avoid coming up with cash out of your pocket. You can always
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
ry to use your own cash to buy down your interest rate as well
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products